Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update

• Published in: Aging clinical and experimental research Vol. 34; no. 11; pp. 2591 - 2602
• Main Authors: Messina, Osvaldo Daniel, Vidal, Maritza, Torres, Jorge A Morales, Vidal, Luis Fernando, Arguissain, Constanza, Pereira, Rosa María, Clark, Patricia, Cerdas Perez, Sonia, Campusano, Claudia, Lazaretti-Castro, Marise, Zerbini, Cristiano, Scali, Juan J, Mendez Sanchez, Lucia, Peralta-Pedrero, Maria L, Cavallo, Andrea, Valdivia Ibarra, Francisco J, Hernandez Pérez, Talina
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer Nature B.V 01-11-2022
• Subjects: Clinical medicine; Evidence-based medicine; Family physicians; Osteoporosis
• DOI: 10.1007/s40520-022-02261-2
• EISSN: 1720-8319
• ISSN: 1594-0667

Guidelines and recommendations developed and endorsed by the International Osteoporosis Foundation (IOF) are intended to provide guidance for particular pattern of practice for physicians who usually prescribe glucocorticoid (GC) therapy, and not to dictate the care of a particular patient. Adherence to the recommendations within this guideline is voluntary and the ultimate determination regarding their application should be made by the physician in light of each patient’s circumstances. Guidelines and recommendations are intended to promote a desirable outcome but cannot guarantee any specific outcome. This guideline and its recommendations are not intended to dictate payment, reimbursement or insurance decisions. Guidelines and recommendations are subjected to periodic revisions as a consequence of the evolution of medicine, technology and clinical practice. A panel of Latin American (LATAM) experts specialized in osteoporosis with recognized clinical experience in managing patients with glucocorticoid-induced osteoporosis (GIO) met to produce evidence-based LATAM recommendations for the diagnosis and management of GIO. These guidelines are particularly intended to general practitioners and primary care physicians who prescribe GC treatments in LATAM to guide their daily clinical practice in terms of evaluation, prevention and treatment of GIO. These recommendations were based on systematic literature review using MEDLINE, EMBASE, SCOPUS and COCHRANE Library database during the period from 2012 to 2021. Randomized clinical trials (RCT), systematic reviews of RCT, controlled observational studies, guidelines and consensus were considered. Based on the review and expert opinion the panel members voted recommendations during two successive rounds of voting by panel members. Agreements for each statement were considered if a concordance of at least 70% was achieved following Delphi methodology. Grading of recommendations was made according to the Oxford Centre for the Evidence-based Medicine (EBM) criteria. Among five GIO guidelines and consensus initially identified, two of them (American College of Rheumatology 2017 and the Brazilian Guidelines 2021) were selected for comparison considering the latter as the most current guides in the LATAM region. Based on this methodology fifty statements were issued. All of them but four (1.20, 1.21, 1.23 and 4.2) attained agreement.